Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2C Tech Corp. Inc.

Preserving retinal cells with injectable nanoparticles

This article was originally published in Start Up

Executive Summary

2C Tech Corp. is developing a non-surgical, nanotechnology-based artificial retinal prostheses designed to overcome the limitations of current, implanted silicon chips and to operate at the cellular level over the entire retina to preserve sight. The start-up’s injectable SeeQ device converts ambient light to electrical energy. As photoreceptors are stimulated by the electrical charge, they release growth factors beneficial for retinal cell preservation.

You may also be interested in...



Artificial Retinal Devices Help The Blind To See

Worldwide rates of all diseases that cause blindness are expected to double by 2020 due to the aging population, making this an area ripe for medical device innovation. A multibillion-dollar market has been built around the surgical correction of "front of the eye" age-related vision disorders such as presbyopia, but the technological evolution in ophthalmology has now reached the back of the eye. Artificial retinal prostheses are an increasingly popular area of investigation. Start-ups hoping to enter this market face daunting R&D, clinical and regulatory hurdles, and will require significant resources. We profile three such companies in this issue: 2C Tech Corp., LambdaVision and Nano Retina.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered. 

OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market

A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel